Business UpdateApr 27, 2026, 07:28 PM
TLX to Host Webinar on PSMA-Targeted Radionuclide Therapy
AI Summary
Telix Pharmaceuticals Limited announced an upcoming educational webinar to discuss the evolution of PSMA-targeted radionuclide therapy and the company's multi-product strategy for prostate cancer. Dr. David N. Cade, Telix Group Chief Medical Officer, will host the discussion with Professor Louise Emmett, who will present data from her OPTIMAL-PSMA investigator-initiated trial of TLX597-Tx. This novel second-generation small molecule candidate is being developed to expand patient access to lutetium therapy, though it has not yet received marketing authorization.
Key Highlights
- Telix to host an educational webinar on PSMA-targeted radionuclide therapy.
- Webinar will explore the evolution of PSMA-targeted therapy and Telix's multi-product approach.
- Dr. David N. Cade (Telix CMO) and Prof. Louise Emmett (St Vincent’s Hospital) to host.
- Prof. Emmett to showcase data from OPTIMAL-PSMA trial of TLX597-Tx.
- TLX597-Tx is a novel second-generation small molecule candidate for lutetium therapy.
- TLX597-Tx has not yet received marketing authorization in any jurisdiction.
- Webinar scheduled for April 30, 2026 (AEST) and April 29, 2026 (EDT).
Price Impact
More from TLX